Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBIT Margin (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed EBIT Margin for 12 consecutive years, with 88.63% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 2588.0% year-over-year to 88.63%, compared with a TTM value of 65.82% through Sep 2025, down 4949.0%, and an annual FY2024 reading of 72.31%, up 6469.0% over the prior year.
  • EBIT Margin was 88.63% for Q3 2025 at Arcadia Biosciences, down from 34.43% in the prior quarter.
  • Across five years, EBIT Margin topped out at 987.87% in Q3 2022 and bottomed at 643.24% in Q1 2021.
  • Average EBIT Margin over 5 years is 98.15%, with a median of 114.51% recorded in 2024.
  • The sharpest move saw EBIT Margin skyrocketed 313865bps in 2021, then plummeted -109550bps in 2023.
  • Year by year, EBIT Margin stood at 373.6% in 2021, then skyrocketed by 105bps to 17.58% in 2022, then soared by 351bps to 79.28% in 2023, then tumbled by -337bps to 187.57% in 2024, then surged by 53bps to 88.63% in 2025.
  • Business Quant data shows EBIT Margin for RKDA at 88.63% in Q3 2025, 34.43% in Q2 2025, and 44.17% in Q1 2025.